# Laboratory Corporation of America Holdings  Share Price Target ‘$245.71’, now 10.6% Upside Potential

- Link: https://www.directorstalkinterviews.com/laboratory-corporation-of-america-holdings-share-price-target-245.71-now-10.6-upside-potential/4121143565
- Published: 2024-02-20T14:46:39+00:00
- Author: Charlotte Edwards

**Laboratory Corporation of America Holdings** with ticker code (LH) now have 14
market analysts covering the stock. The analyst consensus now points to a rating
of ‘buy’. The target price High/Low ranges between $270.00 and $220.00 suggesting
an average analyst share price target price of $245.71. (at the time of writing).
Given that the stocks previous close was at $222.13 this would imply there is now
a potential upside of 10.6%. The day 50 moving average is $223.57 while the 200 
day moving average is $209.09. The company has a market capitalization of 18.18B.
The stock price is currently at: $216.64 USD

 The potential market cap would be $20,105,562,558 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 50.03, revenue per share of $139.63
and a 3.81% return on assets.

Laboratory Corporation of America Holdings is a global life sciences company. The
Company provides information to help doctors, hospitals, pharmaceutical companies,
researchers, and patients make decisions. The Company’s segments include Labcorp
Diagnostics (Dx) and Labcorp Drug Development (DD). The Dx segment is an independent
clinical laboratory business. It offers a menu of frequently requested and specialty
diagnostic tests through an integrated network of primary and specialty laboratories
across the United States. In addition to diagnostic testing along with occupational
and wellness testing for employers and forensic DNA analysis, Dx segment also offers
a range of other testing services. The DD segment is a contract research organizations
business that provides end-to-end drug development services. The DD segment provides
these services predominantly to pharmaceutical, biotechnology and medical device
companies across the world. It serves clients in more than 100 countries.

Share on:
